Basis: FMP quote price / unrounded diluted EPS from four consecutive issuer fiscal quarters. Source: stored company filings and market data; unavailable inputs remain N/A.
The P/E ratio is N/A as of 2026-10-06T20:13:55.911Z.
Calculation as of: 2026-10-06T20:13:55.911Z.
Quote observation: 2026-10-06T20:00:01.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: aebbac3c8f5cd71f6a0736116a7e77570b12e82b9576f853dd4f644618eebaf7
PE RATIO
N/A
PE RATIO AVG TTM
N/A
PE RATIO AVG 3Y
N/A
PE RATIO AVG 5Y
N/A
PE RATIO AVG 10Y
N/A
PE RATIO AVG 15Y
N/A
PE RATIO AVG 20Y
N/A
CURRENT VS TTM AVG
N/A
CURRENT VS 3Y AVG
N/A
CURRENT VS 5Y AVG
N/A
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
Market Cap
$79.61M
PE Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$77.54M
PE Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
| NAME | MARKET CAP | PE RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| vTv Therapeutics Inc. (VTVT) | $78.59M | N/A | N/A | N/A | N/A |
| Sera Prognostics, Inc. (SERA)vs › | $78.29M | N/A | N/A | N/A | N/A |
| Inovio Pharmaceuticals, Inc. (INO)vs › | $78.07M | N/A | N/A | N/A | N/A |
| Acrivon Therapeutics, Inc. Common Stock (ACRV)vs › | $79.61M | N/A | N/A | N/A | N/A |
| Neonc Technologies Holdings, Inc. (NTHI)vs › | $77.54M | N/A | N/A | N/A | N/A |
| Humacyte, Inc. (HUMA)vs › | $80.30M | N/A | 8.03 | 8.03 | 8.03 |
| Outset Medical, Inc. (OM)vs › | $76.74M | N/A | N/A | N/A | N/A |
| Citius Oncology, Inc. (CTOR)vs › | $80.80M | N/A | N/A | N/A | N/A |
| Nutriband Inc. (NTRB)vs › | $81.20M | N/A | N/A | N/A | N/A |
| MediciNova, Inc. (MNOV)vs › | $81.22M | N/A | N/A | N/A | N/A |
Trailing P/E
N/A
Forward P/E
N/A
Forward P/E is calculated using analyst consensus EPS estimates for the current or next fiscal year.
Calculation:
Current Price
$30.03
Forward EPS (Est.)
$-1.41
Forward P/E
N/A
Source: FMP Analyst Consensus Estimates. Forward EPS represents the average analyst estimate for the nearest fiscal year.
PE Ratio = Share Price / Diluted EPS (TTM)
The price-to-earnings ratio measures how much investors pay for each dollar of trailing earnings. A lower PE can indicate a cheaper valuation; a higher PE implies higher growth expectations.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | PE RATIO |
|---|---|
| 2026-08-06 | 1730.50 |
| 2026-08-05 | 1719.50 |
| 2026-08-04 | 1603.00 |
| 2026-08-03 | 1619.50 |
| 2026-07-31 | 1617.50 |
| 2026-07-30 | 1634.00 |
| 2026-07-29 | 1574.00 |
| 2026-07-28 | 1554.00 |
| 2026-07-27 | 1551.00 |
| 2026-07-24 | 1536.50 |
| 2026-07-23 | 1583.00 |
| 2026-07-22 | 1583.50 |
| 2026-07-21 | 1645.50 |
| 2026-07-20 | 1619.00 |
| 2026-07-17 | 1644.00 |
| 2026-07-16 | 1614.50 |
| 2026-07-15 | 1634.50 |
| 2026-07-14 | 1594.00 |
| 2026-07-13 | 1579.00 |
| 2026-07-10 | 1674.50 |
| 2026-07-09 | 1672.00 |
| 2026-07-08 | 1731.50 |
| 2026-07-07 | 1706.00 |
| 2026-07-06 | 1727.00 |
| 2026-07-02 | 1770.00 |
| 2026-07-01 | 1752.50 |
| 2026-06-30 | 1882.50 |
| 2026-06-29 | 1813.50 |
| 2026-06-26 | 1754.00 |
| 2026-06-25 | 1841.00 |
| 2026-06-24 | 1787.00 |
| 2026-06-23 | 1766.50 |
| 2026-06-22 | 1696.00 |
| 2026-06-18 | 1752.00 |
| 2026-06-17 | 1696.00 |
| 2026-06-16 | 1612.00 |
| 2026-06-15 | 1677.00 |
| 2026-06-12 | 1638.50 |
| 2026-06-11 | 1579.50 |
| 2026-06-10 | 1522.00 |
| 2026-06-09 | 1588.50 |
| 2026-06-08 | 1603.00 |
| 2026-06-05 | 1607.00 |
| 2026-06-04 | 1717.50 |
| 2026-06-03 | 1647.00 |
| 2026-06-02 | 1650.00 |
| 2026-06-01 | 1715.00 |
| 2026-05-29 | 1667.50 |
| 2026-05-28 | 1675.00 |
| 2026-05-27 | 1686.00 |
| 2026-05-26 | 1658.00 |
| 2026-05-22 | 1720.50 |
| 2026-05-21 | 1775.00 |
| 2026-05-20 | 1830.00 |
| 2026-05-19 | 1824.50 |
| 2026-05-18 | 1774.50 |
| 2026-05-15 | 1785.00 |
| 2026-05-14 | 1921.50 |
